Literature DB >> 32220930

Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.

Matthew A Sparks1, Andrew South2, Paul Welling3, J Matt Luther4, Jordana Cohen5, James Brian Byrd6, Louise M Burrell7, Daniel Batlle8, Laurie Tomlinson9, Vivek Bhalla10, Michelle N Rheault11, María José Soler12, Sundar Swaminathan13, Swapnil Hiremath14.   

Abstract

Entities:  

Keywords:  ACE inhibitors; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Renin-Angiotensin System; angiotensin; hypertension; renin angiotensin system; severe acute respiratory syndrome coronavirus 2; virology

Mesh：

Substances：

Year:  2020        PMID： 32220930      PMCID： PMC7269218          DOI： 10.2215/CJN.03530320

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  11 in total

1.  Preventing a covid-19 pandemic.

Authors:  John Watkins
Journal:  BMJ       Date:  2020-02-28

2.  Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat.

Authors:  María Paz Ocaranza; Ivan Godoy; Jorge E Jalil; Manuel Varas; Patricia Collantes; Melissa Pinto; Maritza Roman; Cristián Ramirez; Miguel Copaja; Guillermo Diaz-Araya; Pablo Castro; Sergio Lavandero
Journal:  Hypertension       Date:  2006-08-14       Impact factor: 10.190

3.  Myocardial infarction increases ACE2 expression in rat and humans.

Authors:  Louise M Burrell; John Risvanis; Eiji Kubota; Rachael G Dean; Peter S MacDonald; Sai Lu; Christos Tikellis; Sharon L Grant; Rebecca A Lew; A Ian Smith; Mark E Cooper; Colin I Johnston
Journal:  Eur Heart J       Date:  2005-01-25       Impact factor: 29.983

4.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

5.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

6.  Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.

Authors:  Penghui Yang; Hongjing Gu; Zhongpeng Zhao; Wei Wang; Bin Cao; Chengcai Lai; Xiaolan Yang; LiangYan Zhang; Yueqiang Duan; Shaogeng Zhang; Weiwen Chen; Wenbo Zhen; Maosheng Cai; Josef M Penninger; Chengyu Jiang; Xiliang Wang
Journal:  Sci Rep       Date:  2014-11-13       Impact factor: 4.379

7.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.

Authors:  Keiji Kuba; Yumiko Imai; Shuan Rao; Hong Gao; Feng Guo; Bin Guan; Yi Huan; Peng Yang; Yanli Zhang; Wei Deng; Linlin Bao; Binlin Zhang; Guang Liu; Zhong Wang; Mark Chappell; Yanxin Liu; Dexian Zheng; Andreas Leibbrandt; Teiji Wada; Arthur S Slutsky; Depei Liu; Chuan Qin; Chengyu Jiang; Josef M Penninger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

8.  Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease.

Authors:  Jay Ramchand; Sheila K Patel; Piyush M Srivastava; Omar Farouque; Louise M Burrell
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

9.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

10.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962
View more
  40 in total

1.  Authors' Reply.

Authors:  Daniel Batlle; Maria Jose Soler; Paul A Welling; Sundararaman Swaminathan
Journal:  J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 10.121

Review 2.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

3.  Rigor before speculation in COVID-19 therapy.

Authors:  Paul A Welling; Daniel Batlle; James Brian Byrd; Louise M Burrell; Andrew M South; Matthew A Sparks
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-05-01       Impact factor: 5.464

4.  Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic.

Authors:  Shana E Gleeson; Richard N Formica; Ethan P Marin
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-28       Impact factor: 8.237

5.  How COVID-19 Has Changed the Management of Glomerular Diseases.

Authors:  Andrew S Bomback; Pietro A Canetta; Wooin Ahn; Syeda B Ahmad; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-24       Impact factor: 8.237

6.  Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.

Authors:  Henry Sackin
Journal:  Med Hypotheses       Date:  2021-05-12       Impact factor: 1.538

Review 7.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

8.  Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection.

Authors:  Imran Chaudhri; Farrukh M Koraishy; Olena Bolotova; Jeanwoo Yoo; Luis A Marcos; Erin Taub; Haseena Sahib; Michelle Bloom; Sahar Ahmad; Hal Skopicki; Sandeep K Mallipattu
Journal:  Kidney360       Date:  2020-08-27

Review 9.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

Authors:  Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 10.  Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19.

Authors:  Rhian M Touyz; Marcus O E Boyd; Tomasz Guzik; Sandosh Padmanabhan; Linsay McCallum; Christian Delles; Patrick B Mark; John R Petrie; Francisco Rios; Augusto C Montezano; Robert Sykes; Colin Berry
Journal:  CJC Open       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.